Low rate of seroconversion after vaccination with a split virion, adjuvanted pandemic H1N1 influenza vaccine in HIV-1-infected patients.
Identifieur interne : 000338 ( Main/Exploration ); précédent : 000337; suivant : 000339Low rate of seroconversion after vaccination with a split virion, adjuvanted pandemic H1N1 influenza vaccine in HIV-1-infected patients.
Auteurs : Markus Bickel [Allemagne] ; Imke Wieters ; Pavel Khaykin ; Gabi Nisius ; Annette Haberl ; Christoph Stephan ; Nils Von Hentig ; Eva Herrmann ; Hans W. Doerr ; Hans R. Brodt ; Regina AllwinnSource :
- AIDS (London, England) [ 1473-5571 ] ; 2010.
Descripteurs français
- KwdFr :
- Adulte d'âge moyen, Allemagne (épidémiologie), Anticorps antiviraux (sang), Facteurs de l'âge, Femelle, Grippe humaine (), Grippe humaine (épidémiologie), Humains, Mâle, Numération des lymphocytes CD4, Sous-type H1N1 du virus de la grippe A (immunologie), VIH-1 (Virus de l'Immunodéficience Humaine de type 1), Vaccins antigrippaux (administration et posologie), Vaccins antigrippaux (immunologie), Virion (immunologie).
- MESH :
- administration et posologie : Vaccins antigrippaux.
- immunologie : Sous-type H1N1 du virus de la grippe A, Vaccins antigrippaux, Virion.
- sang : Anticorps antiviraux.
- épidémiologie : Allemagne, Grippe humaine.
- Adulte d'âge moyen, Facteurs de l'âge, Femelle, Grippe humaine, Humains, Mâle, Numération des lymphocytes CD4, VIH-1 (Virus de l'Immunodéficience Humaine de type 1).
- Wicri :
- geographic : Allemagne.
English descriptors
- KwdEn :
- Age Factors, Antibodies, Viral (blood), CD4 Lymphocyte Count, Female, Germany (epidemiology), HIV-1, Humans, Influenza A Virus, H1N1 Subtype (immunology), Influenza Vaccines (administration & dosage), Influenza Vaccines (immunology), Influenza, Human (epidemiology), Influenza, Human (prevention & control), Male, Middle Aged, Virion (immunology).
- MESH :
- chemical , administration & dosage : Influenza Vaccines.
- chemical , blood : Antibodies, Viral.
- geographic , epidemiology : Germany.
- epidemiology : Influenza, Human.
- immunology : Influenza A Virus, H1N1 Subtype, Influenza Vaccines, Virion.
- prevention & control : Influenza, Human.
- Age Factors, CD4 Lymphocyte Count, Female, HIV-1, Humans, Male, Middle Aged.
Abstract
OBJECTIVE
To determine rates of seroconversion after single vaccination with a novel split virion, inactivated, adjuvanted pandemic H1N1 influenza vaccine (A/California/7/2009) in HIV-1-infected patients (ClinicalTrials.gov Identifier: NCT01017172).
DESIGN
Single center diagnostic study.
SETTING
Institutional HIV outpatient department of an urban university clinic.
PARTICIPANTS
Adult HIV-1-infected individuals.
INTERVENTION
Serum samples were taken before and 21 days after vaccination.
MAIN OUTCOME MEASURES
Antibody titers determined by hemagglutination inhibition assay. Seroconversion to vaccination was defined by either an antibody titer of 1: 10 or less before and of at least 1: 40 after or at least 1: 10 before and at least four-fold increase in antibody titer 21 days after single vaccination.
RESULTS
One hundred and sixty patients (125 men/35 women) were analyzed. Before vaccination, 23 patients (14.4%) had a hemagglutination inhibition assay titer of at least 1: 40. A median of 22 +/- 3 days after vaccination, 110 (69%) patients seroconverted. Seroconverters were younger (45.1 +/- 10.0 vs. 48.8 +/- 11.3 years; P = 0.04), had a higher CD4 cell count (532 +/- 227 vs. 475 +/- 281 cells/microl; P = 0.03) and were more likely to have received a previous H5N1 vaccination in 2009 (25 vs. 8%; P = 0.02) when compared to nonresponders. No other significant differences were found comparing the two groups (prevaccination hemagglutination inhibition assay titer of > or =1: 40, AIDS, HAART, HIV RNA PCR <50 copies/ml or CD4 nadir, CD4 and CD8 percentage, sex, BMI, chronic hepatitis B or C).
CONCLUSION
Seroconversion after one dose of a split virion, inactivated, adjuvanted pandemic H1N1 influenza vaccine of HIV-infected patients was 69%. Studies to investigate whether a second dose of the vaccine will increase seroconversion rate are needed.
DOI: 10.1097/QAD.0b013e3283398da1
PubMed: 20559034
Affiliations:
Links toward previous steps (curation, corpus...)
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Low rate of seroconversion after vaccination with a split virion, adjuvanted pandemic H1N1 influenza vaccine in HIV-1-infected patients.</title><author><name sortKey="Bickel, Markus" sort="Bickel, Markus" uniqKey="Bickel M" first="Markus" last="Bickel">Markus Bickel</name><affiliation wicri:level="3"><nlm:affiliation>HIVCENTER, Frankfurt, Germany. markus.bickel@hivcenter.de </nlm:affiliation> <country xml:lang="fr">Allemagne</country><wicri:regionArea>HIVCENTER, Frankfurt</wicri:regionArea><placeName><region type="land" nuts="1">Hesse (Land)</region><region type="district" nuts="2">District de Darmstadt</region><settlement type="city">Francfort-sur-le-Main</settlement></placeName></affiliation></author><author><name sortKey="Wieters, Imke" sort="Wieters, Imke" uniqKey="Wieters I" first="Imke" last="Wieters">Imke Wieters</name></author><author><name sortKey="Khaykin, Pavel" sort="Khaykin, Pavel" uniqKey="Khaykin P" first="Pavel" last="Khaykin">Pavel Khaykin</name></author><author><name sortKey="Nisius, Gabi" sort="Nisius, Gabi" uniqKey="Nisius G" first="Gabi" last="Nisius">Gabi Nisius</name></author><author><name sortKey="Haberl, Annette" sort="Haberl, Annette" uniqKey="Haberl A" first="Annette" last="Haberl">Annette Haberl</name></author><author><name sortKey="Stephan, Christoph" sort="Stephan, Christoph" uniqKey="Stephan C" first="Christoph" last="Stephan">Christoph Stephan</name></author><author><name sortKey="Von Hentig, Nils" sort="Von Hentig, Nils" uniqKey="Von Hentig N" first="Nils" last="Von Hentig">Nils Von Hentig</name></author><author><name sortKey="Herrmann, Eva" sort="Herrmann, Eva" uniqKey="Herrmann E" first="Eva" last="Herrmann">Eva Herrmann</name></author><author><name sortKey="Doerr, Hans W" sort="Doerr, Hans W" uniqKey="Doerr H" first="Hans W" last="Doerr">Hans W. Doerr</name></author><author><name sortKey="Brodt, Hans R" sort="Brodt, Hans R" uniqKey="Brodt H" first="Hans R" last="Brodt">Hans R. Brodt</name></author><author><name sortKey="Allwinn, Regina" sort="Allwinn, Regina" uniqKey="Allwinn R" first="Regina" last="Allwinn">Regina Allwinn</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2010">2010</date><idno type="RBID">pubmed:20559034</idno><idno type="pmid">20559034</idno><idno type="doi">10.1097/QAD.0b013e3283398da1</idno><idno type="wicri:Area/Main/Corpus">000325</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Corpus" wicri:corpus="PubMed">000325</idno><idno type="wicri:Area/Main/Curation">000325</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Curation">000325</idno><idno type="wicri:Area/Main/Exploration">000325</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Low rate of seroconversion after vaccination with a split virion, adjuvanted pandemic H1N1 influenza vaccine in HIV-1-infected patients.</title><author><name sortKey="Bickel, Markus" sort="Bickel, Markus" uniqKey="Bickel M" first="Markus" last="Bickel">Markus Bickel</name><affiliation wicri:level="3"><nlm:affiliation>HIVCENTER, Frankfurt, Germany. markus.bickel@hivcenter.de </nlm:affiliation> <country xml:lang="fr">Allemagne</country><wicri:regionArea>HIVCENTER, Frankfurt</wicri:regionArea><placeName><region type="land" nuts="1">Hesse (Land)</region><region type="district" nuts="2">District de Darmstadt</region><settlement type="city">Francfort-sur-le-Main</settlement></placeName></affiliation></author><author><name sortKey="Wieters, Imke" sort="Wieters, Imke" uniqKey="Wieters I" first="Imke" last="Wieters">Imke Wieters</name></author><author><name sortKey="Khaykin, Pavel" sort="Khaykin, Pavel" uniqKey="Khaykin P" first="Pavel" last="Khaykin">Pavel Khaykin</name></author><author><name sortKey="Nisius, Gabi" sort="Nisius, Gabi" uniqKey="Nisius G" first="Gabi" last="Nisius">Gabi Nisius</name></author><author><name sortKey="Haberl, Annette" sort="Haberl, Annette" uniqKey="Haberl A" first="Annette" last="Haberl">Annette Haberl</name></author><author><name sortKey="Stephan, Christoph" sort="Stephan, Christoph" uniqKey="Stephan C" first="Christoph" last="Stephan">Christoph Stephan</name></author><author><name sortKey="Von Hentig, Nils" sort="Von Hentig, Nils" uniqKey="Von Hentig N" first="Nils" last="Von Hentig">Nils Von Hentig</name></author><author><name sortKey="Herrmann, Eva" sort="Herrmann, Eva" uniqKey="Herrmann E" first="Eva" last="Herrmann">Eva Herrmann</name></author><author><name sortKey="Doerr, Hans W" sort="Doerr, Hans W" uniqKey="Doerr H" first="Hans W" last="Doerr">Hans W. Doerr</name></author><author><name sortKey="Brodt, Hans R" sort="Brodt, Hans R" uniqKey="Brodt H" first="Hans R" last="Brodt">Hans R. Brodt</name></author><author><name sortKey="Allwinn, Regina" sort="Allwinn, Regina" uniqKey="Allwinn R" first="Regina" last="Allwinn">Regina Allwinn</name></author></analytic><series><title level="j">AIDS (London, England)</title><idno type="eISSN">1473-5571</idno><imprint><date when="2010" type="published">2010</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Age Factors</term><term>Antibodies, Viral (blood)</term><term>CD4 Lymphocyte Count</term><term>Female</term><term>Germany (epidemiology)</term><term>HIV-1</term><term>Humans</term><term>Influenza A Virus, H1N1 Subtype (immunology)</term><term>Influenza Vaccines (administration & dosage)</term><term>Influenza Vaccines (immunology)</term><term>Influenza, Human (epidemiology)</term><term>Influenza, Human (prevention & control)</term><term>Male</term><term>Middle Aged</term><term>Virion (immunology)</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Adulte d'âge moyen</term><term>Allemagne (épidémiologie)</term><term>Anticorps antiviraux (sang)</term><term>Facteurs de l'âge</term><term>Femelle</term><term>Grippe humaine ()</term><term>Grippe humaine (épidémiologie)</term><term>Humains</term><term>Mâle</term><term>Numération des lymphocytes CD4</term><term>Sous-type H1N1 du virus de la grippe A (immunologie)</term><term>VIH-1 (Virus de l'Immunodéficience Humaine de type 1)</term><term>Vaccins antigrippaux (administration et posologie)</term><term>Vaccins antigrippaux (immunologie)</term><term>Virion (immunologie)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Influenza Vaccines</term></keywords><keywords scheme="MESH" type="chemical" qualifier="blood" xml:lang="en"><term>Antibodies, Viral</term></keywords><keywords scheme="MESH" type="geographic" qualifier="epidemiology" xml:lang="en"><term>Germany</term></keywords><keywords scheme="MESH" qualifier="administration et posologie" xml:lang="fr"><term>Vaccins antigrippaux</term></keywords><keywords scheme="MESH" qualifier="epidemiology" xml:lang="en"><term>Influenza, Human</term></keywords><keywords scheme="MESH" qualifier="immunologie" xml:lang="fr"><term>Sous-type H1N1 du virus de la grippe A</term><term>Vaccins antigrippaux</term><term>Virion</term></keywords><keywords scheme="MESH" qualifier="immunology" xml:lang="en"><term>Influenza A Virus, H1N1 Subtype</term><term>Influenza Vaccines</term><term>Virion</term></keywords><keywords scheme="MESH" qualifier="prevention & control" xml:lang="en"><term>Influenza, Human</term></keywords><keywords scheme="MESH" qualifier="sang" xml:lang="fr"><term>Anticorps antiviraux</term></keywords><keywords scheme="MESH" qualifier="épidémiologie" xml:lang="fr"><term>Allemagne</term><term>Grippe humaine</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Age Factors</term><term>CD4 Lymphocyte Count</term><term>Female</term><term>HIV-1</term><term>Humans</term><term>Male</term><term>Middle Aged</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Adulte d'âge moyen</term><term>Facteurs de l'âge</term><term>Femelle</term><term>Grippe humaine</term><term>Humains</term><term>Mâle</term><term>Numération des lymphocytes CD4</term><term>VIH-1 (Virus de l'Immunodéficience Humaine de type 1)</term></keywords><keywords scheme="Wicri" type="geographic" xml:lang="fr"><term>Allemagne</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en"><p><b>OBJECTIVE</b></p><p>To determine rates of seroconversion after single vaccination with a novel split virion, inactivated, adjuvanted pandemic H1N1 influenza vaccine (A/California/7/2009) in HIV-1-infected patients (ClinicalTrials.gov Identifier: NCT01017172).</p></div><div type="abstract" xml:lang="en"><p><b>DESIGN</b></p><p>Single center diagnostic study.</p></div><div type="abstract" xml:lang="en"><p><b>SETTING</b></p><p>Institutional HIV outpatient department of an urban university clinic.</p></div><div type="abstract" xml:lang="en"><p><b>PARTICIPANTS</b></p><p>Adult HIV-1-infected individuals.</p></div><div type="abstract" xml:lang="en"><p><b>INTERVENTION</b></p><p>Serum samples were taken before and 21 days after vaccination.</p></div><div type="abstract" xml:lang="en"><p><b>MAIN OUTCOME MEASURES</b></p><p>Antibody titers determined by hemagglutination inhibition assay. Seroconversion to vaccination was defined by either an antibody titer of 1: 10 or less before and of at least 1: 40 after or at least 1: 10 before and at least four-fold increase in antibody titer 21 days after single vaccination.</p></div><div type="abstract" xml:lang="en"><p><b>RESULTS</b></p><p>One hundred and sixty patients (125 men/35 women) were analyzed. Before vaccination, 23 patients (14.4%) had a hemagglutination inhibition assay titer of at least 1: 40. A median of 22 +/- 3 days after vaccination, 110 (69%) patients seroconverted. Seroconverters were younger (45.1 +/- 10.0 vs. 48.8 +/- 11.3 years; P = 0.04), had a higher CD4 cell count (532 +/- 227 vs. 475 +/- 281 cells/microl; P = 0.03) and were more likely to have received a previous H5N1 vaccination in 2009 (25 vs. 8%; P = 0.02) when compared to nonresponders. No other significant differences were found comparing the two groups (prevaccination hemagglutination inhibition assay titer of > or =1: 40, AIDS, HAART, HIV RNA PCR <50 copies/ml or CD4 nadir, CD4 and CD8 percentage, sex, BMI, chronic hepatitis B or C).</p></div><div type="abstract" xml:lang="en"><p><b>CONCLUSION</b></p><p>Seroconversion after one dose of a split virion, inactivated, adjuvanted pandemic H1N1 influenza vaccine of HIV-infected patients was 69%. Studies to investigate whether a second dose of the vaccine will increase seroconversion rate are needed.</p></div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">20559034</PMID><DateCompleted><Year>2010</Year><Month>12</Month><Day>30</Day></DateCompleted><DateRevised><Year>2010</Year><Month>06</Month><Day>18</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1473-5571</ISSN><JournalIssue CitedMedium="Internet"><Volume>24</Volume><Issue>9</Issue><PubDate><Year>2010</Year><Month>Jun</Month><Day>01</Day></PubDate></JournalIssue><Title>AIDS (London, England)</Title><ISOAbbreviation>AIDS</ISOAbbreviation></Journal><ArticleTitle>Low rate of seroconversion after vaccination with a split virion, adjuvanted pandemic H1N1 influenza vaccine in HIV-1-infected patients.</ArticleTitle><Pagination><MedlinePgn>F31-5</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1097/QAD.0b013e3283398da1</ELocationID><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">To determine rates of seroconversion after single vaccination with a novel split virion, inactivated, adjuvanted pandemic H1N1 influenza vaccine (A/California/7/2009) in HIV-1-infected patients (ClinicalTrials.gov Identifier: NCT01017172).</AbstractText><AbstractText Label="DESIGN" NlmCategory="METHODS">Single center diagnostic study.</AbstractText><AbstractText Label="SETTING" NlmCategory="METHODS">Institutional HIV outpatient department of an urban university clinic.</AbstractText><AbstractText Label="PARTICIPANTS" NlmCategory="METHODS">Adult HIV-1-infected individuals.</AbstractText><AbstractText Label="INTERVENTION" NlmCategory="METHODS">Serum samples were taken before and 21 days after vaccination.</AbstractText><AbstractText Label="MAIN OUTCOME MEASURES" NlmCategory="METHODS">Antibody titers determined by hemagglutination inhibition assay. Seroconversion to vaccination was defined by either an antibody titer of 1: 10 or less before and of at least 1: 40 after or at least 1: 10 before and at least four-fold increase in antibody titer 21 days after single vaccination.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">One hundred and sixty patients (125 men/35 women) were analyzed. Before vaccination, 23 patients (14.4%) had a hemagglutination inhibition assay titer of at least 1: 40. A median of 22 +/- 3 days after vaccination, 110 (69%) patients seroconverted. Seroconverters were younger (45.1 +/- 10.0 vs. 48.8 +/- 11.3 years; P = 0.04), had a higher CD4 cell count (532 +/- 227 vs. 475 +/- 281 cells/microl; P = 0.03) and were more likely to have received a previous H5N1 vaccination in 2009 (25 vs. 8%; P = 0.02) when compared to nonresponders. No other significant differences were found comparing the two groups (prevaccination hemagglutination inhibition assay titer of > or =1: 40, AIDS, HAART, HIV RNA PCR <50 copies/ml or CD4 nadir, CD4 and CD8 percentage, sex, BMI, chronic hepatitis B or C).</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Seroconversion after one dose of a split virion, inactivated, adjuvanted pandemic H1N1 influenza vaccine of HIV-infected patients was 69%. Studies to investigate whether a second dose of the vaccine will increase seroconversion rate are needed.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Bickel</LastName><ForeName>Markus</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>HIVCENTER, Frankfurt, Germany. markus.bickel@hivcenter.de </Affiliation> </AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wieters</LastName><ForeName>Imke</ForeName><Initials>I</Initials></Author><Author ValidYN="Y"><LastName>Khaykin</LastName><ForeName>Pavel</ForeName><Initials>P</Initials></Author><Author ValidYN="Y"><LastName>Nisius</LastName><ForeName>Gabi</ForeName><Initials>G</Initials></Author><Author ValidYN="Y"><LastName>Haberl</LastName><ForeName>Annette</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Stephan</LastName><ForeName>Christoph</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Von Hentig</LastName><ForeName>Nils</ForeName><Initials>N</Initials></Author><Author ValidYN="Y"><LastName>Herrmann</LastName><ForeName>Eva</ForeName><Initials>E</Initials></Author><Author ValidYN="Y"><LastName>Doerr</LastName><ForeName>Hans W</ForeName><Initials>HW</Initials></Author><Author ValidYN="Y"><LastName>Brodt</LastName><ForeName>Hans R</ForeName><Initials>HR</Initials></Author><Author ValidYN="Y"><LastName>Allwinn</LastName><ForeName>Regina</ForeName><Initials>R</Initials></Author></AuthorList><Language>eng</Language><DataBankList CompleteYN="Y"><DataBank><DataBankName>ClinicalTrials.gov</DataBankName><AccessionNumberList><AccessionNumber>NCT01017172</AccessionNumber></AccessionNumberList></DataBank></DataBankList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>AIDS</MedlineTA><NlmUniqueID>8710219</NlmUniqueID><ISSNLinking>0269-9370</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000914">Antibodies, Viral</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007252">Influenza Vaccines</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CitationSubset>X</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>AIDS. 2010 Aug 24;24(13):2142-3</RefSource><PMID Version="1">20679764</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000367" MajorTopicYN="N">Age Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000914" MajorTopicYN="N">Antibodies, Viral</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018791" MajorTopicYN="N">CD4 Lymphocyte Count</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005858" MajorTopicYN="N" Type="Geographic">Germany</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015497" MajorTopicYN="Y">HIV-1</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D053118" MajorTopicYN="N">Influenza A Virus, H1N1 Subtype</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007252" MajorTopicYN="N">Influenza Vaccines</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007251" MajorTopicYN="N">Influenza, Human</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000517" MajorTopicYN="Y">prevention & control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014771" MajorTopicYN="N">Virion</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2010</Year><Month>6</Month><Day>19</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2010</Year><Month>6</Month><Day>19</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2010</Year><Month>12</Month><Day>31</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">20559034</ArticleId><ArticleId IdType="doi">10.1097/QAD.0b013e3283398da1</ArticleId><ArticleId IdType="pii">00002030-201006010-00001</ArticleId></ArticleIdList></PubmedData></pubmed><affiliations><list><country><li>Allemagne</li></country><region><li>District de Darmstadt</li><li>Hesse (Land)</li></region><settlement><li>Francfort-sur-le-Main</li></settlement></list><tree><noCountry><name sortKey="Allwinn, Regina" sort="Allwinn, Regina" uniqKey="Allwinn R" first="Regina" last="Allwinn">Regina Allwinn</name><name sortKey="Brodt, Hans R" sort="Brodt, Hans R" uniqKey="Brodt H" first="Hans R" last="Brodt">Hans R. Brodt</name><name sortKey="Doerr, Hans W" sort="Doerr, Hans W" uniqKey="Doerr H" first="Hans W" last="Doerr">Hans W. Doerr</name><name sortKey="Haberl, Annette" sort="Haberl, Annette" uniqKey="Haberl A" first="Annette" last="Haberl">Annette Haberl</name><name sortKey="Herrmann, Eva" sort="Herrmann, Eva" uniqKey="Herrmann E" first="Eva" last="Herrmann">Eva Herrmann</name><name sortKey="Khaykin, Pavel" sort="Khaykin, Pavel" uniqKey="Khaykin P" first="Pavel" last="Khaykin">Pavel Khaykin</name><name sortKey="Nisius, Gabi" sort="Nisius, Gabi" uniqKey="Nisius G" first="Gabi" last="Nisius">Gabi Nisius</name><name sortKey="Stephan, Christoph" sort="Stephan, Christoph" uniqKey="Stephan C" first="Christoph" last="Stephan">Christoph Stephan</name><name sortKey="Von Hentig, Nils" sort="Von Hentig, Nils" uniqKey="Von Hentig N" first="Nils" last="Von Hentig">Nils Von Hentig</name><name sortKey="Wieters, Imke" sort="Wieters, Imke" uniqKey="Wieters I" first="Imke" last="Wieters">Imke Wieters</name></noCountry><country name="Allemagne"><region name="Hesse (Land)"><name sortKey="Bickel, Markus" sort="Bickel, Markus" uniqKey="Bickel M" first="Markus" last="Bickel">Markus Bickel</name></region></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/GrippeAllemagneV3/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000338 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000338 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= GrippeAllemagneV3
|flux= Main
|étape= Exploration
|type= RBID
|clé= pubmed:20559034
|texte= Low rate of seroconversion after vaccination with a split virion, adjuvanted pandemic H1N1 influenza vaccine in HIV-1-infected patients.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:20559034" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \
| NlmPubMed2Wicri -a GrippeAllemagneV3
| This area was generated with Dilib version V0.6.35. |  |